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Early diagnosis of Parkinson’s disease (PD) offers perhaps, the most promising route to
a successful clinical intervention, and the use of an animal model exhibiting symptoms
comparable to those observed in PD patients in the early stage of the disease,
may facilitate screening of novel therapies for delaying the onset of more debilitating
motor and behavioral abnormalities. In this study, a rat model of pre-motor PD was
used to study the etiology of hyposmia, a non-motor symptom linked to the early
stage of the disease when the motor symptoms have yet to be experienced. The
study focussed on determining the effect of a partial reduction of both dopamine and
noradrenaline levels on the olfactory cortex. Neuroinflammation and striking structural
changes were observed in the model. These changes were prevented by treatment with
a neuroprotective drug, a glucagon-like peptide-1 (GLP1) receptor agonist, exendin-4
(EX-4).
Keywords: olfaction, interneurons, extracellular matrix, perineuronal nets, early stage Parkinson’s disease, GLP-1
agonist, exendin-4
INTRODUCTION
Parkinson’s disease (PD) is a highly debilitating neurodegenerative disorder associated with
degeneration of the nigrostriatal dopaminergic pathway, with no present cure. PD is now thought
to be, in the vast majority of cases, the result of an interplay between a genetic pre-disposition,
neuroinflammation, and very probably, some form of neurotoxicity (Athauda and Foltynie, 2015;
Maiti et al., 2017; Shihabuddin et al., 2018 for review). However, the cause and mechanisms behind
the progression of PD remain unclear. The staging procedure described by Braak et al. (2003, 2004)
and Braak and Del Tredici (2017) reported a neurone-to-neurone spread of α-synuclein-containing
bodies (Lewy pathology – LP) from the enteric nervous system and olfactory system to the
central nervous system (CNS) that was correlated with the appearance and severity of both
motor and non-motor symptoms of PD. The reliability of this staging system, however, has been
challenged over the years with evidence suggesting that the staging of LP may be governed by a
combination of selective vulnerability and a possible lack of compensatory mechanisms in place in
regions with low synaptic connectivity (Halliday and McCann, 2009; Hunn et al., 2015; Surmeier
et al., 2017; proposed by “threshold” theory: Engelender and Isacson, 2017; Rietdijk et al., 2017;
Jellinger, 2018) rather than the entry of pathogens via the olfactory bulb (OB) (Rey et al., 2018 for
review). Nevertheless, there is an agreement that olfactory structures, including the OB, anterior
olfactory nucleus (AON) and piriform cortex (PC), are affected in a prodromal phase in which the
appearance of hyposmia, a non-motor symptom, precedes the first signs of motor dysfunctions
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by several years (Fullard et al., 2017; Schapira et al., 2017).
As motor function is the consequence of neuronal loss of
dopaminergic neurones in the substantia nigra pars compacta
(SNc), the most common treatment for PD is temporary
replacement of brain dopamine (DA), transient reactivation
of DA function, providing a temporary, though imperfect
restoration of movement (Stocchi et al., 2008; Pahwa and Lyons,
2009; Maiti et al., 2017 for review). However, the pathology of
PD encompasses a much wider neurological basis and range of
non-motor symptoms (NMS), including hyposmia, that cannot
be accounted for by DA loss alone and are linked to depletion
of other key brain neurotransmitters such as noradrenaline
(NA), 5-hydroxytryptamine (5-HT), acetylcholine (ACh) and
γ-aminobutyric acid (GABA) (Hou and Lai, 2007; Delaville
et al., 2011; Doty, 2012, 2017; Jellinger, 2015; Błaszczyk, 2016;
Schapira et al., 2017). The degree of involvement of NMS in the
progression of the disease is still poorly understood and clear
insights on their neuropathobiology (focussing on NMS), that
are features of prodromal PD, like the loss of smell, are needed.
Early involvement of olfactory structures in early PD, mainly
OB, and AON, has been studied extensively (Ross et al., 2008;
Doty, 2012; Schapira et al., 2017; Rey et al., 2018), however,
little is known about the pathology in the olfactory cortex
despite the known presence of dopaminergic and noradrenergic
inputs from the SNc and locus coeruleus (LC) into this region
(Fallon and Moore, 1978). In view of these considerations, a rat
neurotoxin-based model of pre-motor PD presenting a partial
reduction of both DA and NA levels and displaying hyposmia and
cognitive deficits with absence of motor symptoms was used to
determine potential structural and cellular changes in the PC in
the early stage of the disease. Of particular interest was the study
of the effect of partial DA and NA denervation on this region, the
presence of neuroinflammation following neuronal degeneration,
the distributions of GABAergic interneurons, that have been
shown to be affected in olfactory pathways of both genetic PD
models and PD patients (Ubeda-Banon et al., 2010; Doty, 2012),
and the integrity of perineuronal nets (PNNs), a component of
the extracellular matrix (ECM) enveloping these neurones (Alpár
et al., 2006; Ajmo et al., 2008). Although a disruption of the
PNNs appears to be at the root of many neurological disorders
(Baig et al., 2005; Hobohm et al., 2005; Berretta et al., 2015), their
involvement in the early stages of PD remains to be determined.
As non-motor symptoms, particularly hyposmia, emerge
many years before diagnosis, the potential window of
opportunities to prevent or slow the progression of the
disease has led to an increased research activity to explore
novel targets and find new therapeutic drugs. One such drug,
exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) receptor
agonist, currently in clinical use for type II diabetes, has
demonstrated neuroprotective effects in several animal models
of PD (Bertilsson et al., 2008; Harkavyi et al., 2008; Kim et al.,
2009, 2017; Li et al., 2009; Cao et al., 2016; Chen et al., 2018;
Yun et al., 2018). These data, together with its excellent safety
profile (Bertilsson et al., 2008; Harkavyi et al., 2008; Kim
et al., 2009; Li et al., 2009; MacConell et al., 2015; Cao et al.,
2016; Yun et al., 2018), even at high doses (Rocha-Ferreira
et al., 2018) and its ability to pass the blood brain barrier
(Kastin and Akerstrom, 2003; Athauda et al., 2017a; Zanotto
et al., 2017), supported its use in clinical trials in patients with PD
(Aviles-Olmos et al., 2013, 2014; Athauda et al., 2017a). Patients
that received EX-4 showed improvements in motor symptoms,
cognition, depression and sleep quality compared with patients
treated with conventional PD medication (Aviles-Olmos et al.,
2013, 2014). EX-4 also improved off-medication motor scores
after 48 weeks’ exposure and 12 weeks wash-out in PD patients
compared with placebo (Athauda et al., 2017a,b). However, the
effect of EX-4 on the underlying pathophysiology in PD patients
remains unclear. The protective effects of EX-4 (Athauda and
Foltynie, 2016a,b), the known presence of GLP-1 receptors
(GLP-1Rs) in the PC (Cork et al., 2015) and the potential role of
these receptors in olfaction (Llewellyn-Smith et al., 2011; Cork
et al., 2015; Trapp and Cork, 2015) led us to study the effect
of EX-4 on the structural changes observed in the olfactory
cortex of the pre-motor model and the associated olfactory and
behavioral consequences of the dual toxin treatment.
MATERIALS AND METHODS
Animals
All procedures used throughout this study were carried out
according to the British Home Office regulations with regard
to the Animal Scientific Procedures Act 1986. Male Wistar rats
weighing 200–250 g (Harlan Laboratories, Inc., United Kingdom)
were kept under constant conditions of humidity (40–60%),
temperature (18–22◦C) and a 12 h light-dark cycle.
Stereotaxic Surgery and Drug
Administration
The protocol used for toxin administration is presented in
Figure 1. Intraperitoneal administration of the noradrenergic
neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine
(DSP-4, Sigma-Aldrich) at a dose of 25 mg/kg, was performed
4 days prior to the dopaminergic neurotoxin insult with
6-hydroxydopamine (6-OHDA). This injection was carried out
to induce partial degeneration of noradrenergic cells in the
CNS, mainly those in the LC (Supplementary Figure S1; Ross
and Stenfors, 2015). Previous studies showed that high doses
of DSP-4 (50 mg/kg) may result in an increase in neophobia,
defensive behavior, an increased aggressiveness and an alteration
of danger perception (Delini-Stula et al., 1984; Harro et al.,
1995). However, the low dose of DSP-4 (25 mg/kg) used in
this study did not result in any adverse effects or change in
behavior patterns (no increased grooming activities, number of
stools, no difference in behavioral pattern following open field or
sucrose preference tests). Stereotaxic surgery was then performed
to administer bilateral injections of either 6-OHDA (Sigma-
Aldrich – dissolved in saline solution containing 0.9% ascorbic
acid) or saline containing 0.9% ascorbic acid for controls. The
optimum doses for DSP-4 and 6-OHDA were chosen to induce
partial reduction of NA and DA levels, respectively, based
on previous studies (Jonsson et al., 1981; Przedborski et al.,
1995), mimicking the early stage of the disease. Animals were
anaesthetized using isoflurane (5% v/v in O2 for induction and
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FIGURE 1 | Protocol for dual neurotoxin administration in rats to generate a pre-motor PD model. Behavioral testing (sucrose preference test, rotarod, novel object
recognition, hidden food test, habituation/dishabituation test) was carried out before, after toxins and after the 7-day treatment with exendin-4 (EX-4). The study
included five experimental groups: sham, sham + EX-4, 6-OHDA + DSP-4 (model), 6-OHDA + DSP-4 + EX-4 (model + EX-4) and 6-OHDA + DSP-4
+ EX-4 + EX9-39 (model + EX-4 + EX9-39). Histological procedures occurred after animals were culled at days 23–24.
2% v/v in O2 for maintenance) delivered through a fitted nose
mask and rats were secured to a stereotaxic frame using blunt ear
bars (David Kopf, United States). Each animal received 15 µg of
6-OHDA per striatum (or vehicle) at a flow rate of 1 µL/min−1
to induce partial destruction of the nigro-striatal dopaminergic
system. The following coordinates from the atlas of Paxinos
and Watson (1982) were used to locate the ventrolateral area of
the dorsal striatum, from Bregma: AP +1.0 mm, ML +3.0 mm,
DV −6.5 mm. Animals were closely monitored for a week
following the surgical procedures. EX-4 (Sigma-Aldrich) was
administered twice daily via intraperitoneal injection (with saline
as a vehicle) at a dose of 0.5 µg/kg for a period of 7 days, one
week after stereotaxic surgeries. The GLP-1R antagonist EX9-39
(Sigma-Aldrich – 2 µg/kg with saline as a vehicle) was injected
prior to EX-4 injection twice daily for 7 days.
In this study, rats were divided into five experimental groups
(Figure 1): sham (n = 10), sham+ EX-4 (n = 10), model (n = 10),
model + EX-4 (n = 10) and model + EX-4 + EX9-39 2 µg/kg
(n = 5).
Behavioral Experiments
All experimental groups were subjected to behavioral tests
prior to the start of the procedures, 5–7 days after stereotaxic
injections of 6-OHDA and after the 7-day treatment with either
saline, EX-4 or EX-4 + EX9-39 (see Figure 1). Rats were
subdivided into groups that underwent only one behavioral test
[sucrose preference test, Novel Object Recognition (NOR) test,
or rotarod] to prevent confounding results. However, all animals
were assessed for hyposmia with two tests: the buried food test
and habituation/dishabituation test. All data are represented as
mean± standard error of the mean (SEM).
Rats were habituated in the testing arena twice for 5 min the
day before the buried food test and fasted overnight. Animals
were then placed in the same environment containing a “treat”
(banana chips) hidden under the sawdust and the time taken
to locate the treat was assessed. Animals were given 5 min to
locate the treat and those unable to find it during this period were
given a score of 300 s. Five animals per experimental group were
also tested with the treat in view. The habituation/dishabituation
test was used to determine whether the animals were able to
detect and differentiate different odors as previously described
(Arbuckle et al., 2015). Rats were habituated in the testing arena
for 30 min. Each animal was then exposed to an odor or water (for
control) on a cotton swab for 2 min in three consecutive trials
with a minute between trials and the total time spent exploring
the cotton swab was measured. Both non-social (paprika and
vanilla) and social odors were used in this test. Two social odors
(social 1 and social 2) were obtained by wiping a cotton swab
across the bottom of two dirty cages that contained an equal
number of male rats.
Level of anxiety was tested using a sucrose preference test. Rats
were first exposed to a 4-day habituation phase in which they were
provided with two bottles, one containing water and the other
containing a 1% sucrose solution. After the habituation phase,
the animals were individually housed and sucrose consumption
was measured over a two-day period by weighing the bottles
daily. Sucrose preference was calculated as the percentage of total
sucrose solution consumed compared with total fluid intake.
Cognition was measured using a Novel Objection Recognition
(NOR) test. Rats were placed in the testing arena for a period
of 5 min for 2 days prior to testing. The task consisted of
three phases: habituation, familiarization and test phase. Animals
were first allowed to explore the testing arena freely, in the
absence of objects, for 10 min. Animals were then removed from
the arena and placed in their holding cages. Rats were then
reintroduced into the arena containing two identical objects for
a period of 5 min. One hour later, rats were returned to the
arena that contained one familiar and one novel object for 5 min.
A discrimination ratio (DR) was calculated by dividing the time
spent exploring the novel object by the total exploration time.
Motor coordination was assessed using a Rotarod Test.
Animals were placed on an accelerating rotating rod (drop height
30 cm) and the speed at which the animals fell off was noted.
Rats were subjected to a training period of three consecutive days
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prior to the testing day. On the first day of training, animals
were placed on a rod rotating at a constant slow speed in three
consecutive trials. On the second and third training day, animals
were placed on the rod before starting acceleration (start speed of
4 rpm, acceleration rate 9 rpm/min) until they fell off in three
consecutive trials. On the day of testing, animals were placed
on the accelerating rod (start speed of 4 rpm, acceleration rate
9 rpm/min) and the time of fall was recorded.
High Performance Liquid
Chromatography (HPLC)
Dissected rat brain tissues (SNc, striatum and PC) were weighed
and homogenized in appropriate volumes of homogenizing
solution (0.1 M perchloric acid containing 400 mM sodium
metabisulphite) and then microcentrifuged. Determination of
DA and NA levels was performed with a Jasco PU-980
pump HPLC coupled to electrochemical detection (Coulochem
II-ESA model 5011 analytical cell), equipped with a Capital
Hypersil column (250 mm x 4.6 mm id 5 µm) using a
mobile phase (0.01 M sodium dihydrogen orthophosphate
dehydrate, 0.9 mM 1-octanesulfonic acid sodium salt, 0.1%
dibutylamine, 12.5% methanol, pH 3.2) at a flow rate of 1 ml
min−1. Concentrations of the monoamines were expressed as
ng/g ± SEM and were calculated by reference to an internal
standard, dihydroxybenzylamine (DHBA – 0.5 ng). Data were
captured using Antec’s Scientific Clarity software.
Immunohistochemistry
Neuronal Distributions
All histological procedures used in this study have been described
previously (Hughes et al., 2000). Brain slices were obtained
from rats that were anaesthetized by inhalation of isoflurane
and intraperitoneal injection of Euthatal (Merial, Harlow,
United Kingdom) (60 mg/kg) and then perfused transcardially
with ice-cold oxygenated artificial cerebrospinal fluid (ACSF)
containing in mM: 124 NaCl, 25.5 NaHCO3, 3.3 KCl, 1.2
KH2PO4, 1 MgSO4, 2.5 CaCl2, 15 mM D-Glucose equilibrated
with 95% O2/5% CO2. Brains were then removed and fixed
overnight (4% paraformaldehyde, 0.2% saturated picric acid
solution, 0.025% glutaraldehyde solution in 0.1 M Phosphate
buffer). Fifty micrometers parasagittal sections containing the
piriform cortex were cut with a vibratome (Agar Scientific). One
in 12 sections were collected and 3–4 slices per animal were
used per staining. Sections were incubated first in 1% H2O2
for 30 min and then in 1% sodium borohydride (NaBH4) for
30 min to decrease background staining and then in either 1%
bovine serum albumin for the Biotinylated Wisteria floribunda
lectin (WFA) staining used to label PNNs or in 10% normal
goat serum (NGS) for all other antibodies for another 30 min
to block non-specific antibody binding. Sections were incubated
overnight at 4oC in a mixture of primary antibodies and triton
X-100 (Sigma-Aldrich) (1% Triton for GAD-67 – 0.1% for
all other antibodies) made up in phosphate buffer solution.
Primary antibodies used in this study and antibody specificity
are listed in Table 1. Sections for fluorescence microscopy were
then incubated for 2 h in a mixture of fluorescently labeled
secondary antibodies, anti-mouse fluorescein isothiocyanate
(FITC) and goat anti-rabbit Texas Red (TR) made up in
PBS. All fluorescently labeled sections were then mounted on
slides in Vectashield (Vector Laboratories) and studied using
a confocal microscope (Zeiss LSM 710). Six to seven Z-stacks
from the piriform cortex of each slice in each animal (1
in 15 PC sections – 3–4 slices per animal) were obtained
using a 10× objective and immunopositive cell bodies were
counted using a Cell Counting plug in ImageJ software.
Cellular densities were expressed as the number of cells per
mm3 ± SEM.
Neuroinflammation Staining
Following incubation in primary antibodies, sections for
immunoperoxidase staining (glial fibrillary acidic protein
(GFAP) and ionized calcium-binding adapter molecule 1 (Iba1)
staining) were incubated overnight in secondary antibodies,
biotinylated goat anti-mouse or anti-rabbit antibody (1:500,
Vector Laboratories) made up in PBS. To visualize the stained
neurones, sections were incubated first in ABC (Vector
Laboratories) for 2 h and then in 3,3′-diaminobenzidine
(DAB – Sigma-Aldrich). H2O2 was added to the DAB solution
to allow the reaction until the filled cells were sufficiently labeled.
Sections from the different experimental groups (1 in 12 PC
sections – 4 slices per animal) were processed together using
the same immunoreagents and the DAB reaction was stopped
at the same time to allow comparison between groups. Sections
were then placed onto Superfrost slides, dehydrated, cleared
with Histoclear and mounted using DPX (Sigma-Aldrich).
Levels of GFAP and Iba1 immunohistochemical staining
were measured by quantitative thresholding image analysis as
previously described (Rahim et al., 2012). Four non-overlapping
images of the piriform cortex in each section were captured
using a DMR microscope and Leica Application Suite V4
(Leica Microsystems) at 10× magnification with constant
light intensity, microscope calibration and video camera
settings. Image-Pro Premier (Media Cybernetics, Cambridge,
United Kingdom) was used to analyze the images and measure
immunoreactivity using a constant threshold that was applied
to all images for each respective antigen. Data are presented
as the mean percentage area of immunoreactivity ± SEM.
3D reconstructions of Iba1-immunopositive cells (n = 8
per experimental group) were obtained with a Neurolucida
software (MBF Bioscience) and morphological characteristics
of these cells were analyzed using Sholl and branched
structure analyses. Data are represented as mean ± standard
deviation (SD).
Tyrosine Hydroxylase (TH) staining
TH immunostaining was carried out on coronal sections
containing SNc and ventral tegmental area (VTA) according
to the immunoperoxidase protocol described above. One in
four slices per animal were collected and processed. Sections
were dehydrated and mounted using DPX. The optical
fractionator probe was used to determine the number of
TH-immunopositive neurons in the SNc and VTA (Stereo
Investigator, MicroBrightField) using a Nikon microscope
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TABLE 1 | List of primary antibodies used in this study.
Antibody Immunogen Manufacturer/
Investigator
Species Catalog/lot
number
Dilutions
Parvalbumin Purified frog muscle parvalbumin Sigma Rabbit P3088
Clone PARV-9
Lot #048K4752
1:1000
CCK Synthetic human gastrin/CCK 2-17 conjugated
with carbodiimide to keyhole limpet
hemocyanin
Cure Digestive
Diseases Research
Center, UCLA
Mouse #9303 1:1000
Calretinin Recombinant rat calretinin Millipore Rabbit AB5054/
LV1532272
Lot #2049207
1:1000
Calbindin Recombinant chick CaBP Gift from Dr. K.
Baimbridge (2000)
Rabbit R9501 1:1000
Somatostatin Somatostatin-14 conjugated to keyhole limpet
hemocyanin
Gift from Dr. A.
Duchan (2000)
Mouse 1:3000
NPY Neuropeptide Y coupled with bovine
thyroglobulin with glutaraldehyde
Immunostar Rabbit 22940
Lot #1112001
1:1000
VIP Synthetic porcine VIP conjugated to bovine
thyroglobulin with carbodiimide linker
Immunostar Rabbit 20077
Lot#1129001
1:1000
GAD67 Synthetic peptide from mouse GAD67 (amino
acids (87-106)
Sigma Mouse MAB 5406
Lot #2549419
1:1500
TH SDS-denatured rat tyrosine hydroxylase purified
from pheochromocytoma
Sigma Rabbit T8700-1VL
Lot #SLBL8773V
1:7500
GFAP Purified glial filament Millipore Mouse MAB 3402
#2549419
1:7500
Iba1 C-terminus of Iba1 Wako Rabbit 019-19741 1:1000
coupled to a computer-controlled x-y-z motorized stage and an
MBF video camera system. Unbiased stereology was carried out
on five slices per animal (n = 6 per experimental group) with
the following parameters: counting frame 60 µm × 60 µm;
grid size 200 µm × 200 µm; section thickness 50 µm,
dissector height 12 µm. Only neurones with visible nuclei and
dendrites were counted. Data are displayed as cell density per
mm3 ± SEM.
Statistics
All data in this study were analyzed using IBM SPSS Statistics
Version 22.0. The Shapiro–Wilk test and the Kolmogorov–
Smirnov test were carried out prior to statistical analysis to
determine whether the data followed a normal distribution.
The parametric one-way ANOVA, repeated measured
ANOVA or unpaired t-test were then used when the data
followed a normal distribution and the non-parametric
Kruskal–Wallis test were use in case of a non-normal
distribution.
RESULTS
Effect of DSP-4 and Bilateral 6-OHDA
Injections on Brain Dopaminergic and
Noradrenergic Levels in the Pre-motor
PD Model
Immunohistochemical staining of TH cells in the SNc
(Figure 2A) and unbiased stereology (Figure 2B) revealed
that dopaminergic lesions in the pre-motor model significantly
decreased TH immunoreactivity by 43.5 ± 5.3% in the SNc
compared with that observed in sham animals (P < 0.01). The
toxin injections had no effect on the number of TH-positive cells
in the VTA (Supplementary Figure S2). Injections of EX-4 in
the pre-motor model partially prevented the neuronal loss in
the SNc (Figures 2A,B). Levels of DA and NA, measured by
HPLC in the SNc were significantly reduced by 47.6 ± 2.4 and
49.9 ± 1.6%, respectively, in the pre-motor model compared
with those measured in the sham animals (unpaired t-test,
P < 0.01) (Figures 2C,D). HPLC measurements of DA and NA
in the piriform cortex revealed a reduction of 39.8 ± 1.1 and
40 ± 1.4%, respectively, in the models compared with those
in the shams (unpaired t-test, PDA < 0.0001, PNA < 0.001)
(Figures 2C,D).
The Pre-motor PD Model Did Not Display
Anhedonia or Motor Symptoms
Animals were subjected to behavioral tests to validate the
presence of non-motor symptoms and absence of motor
symptoms in the pre-motor PD model. These tests were
carried out at baseline, 7 days after surgery and 18 days
after surgery (See Figure 1 for protocol). The level of
anhedonia in all experimental groups was investigated using
the sucrose preference test. One-way ANOVA revealed that
groups did not show any statistically significant differences
at 7 days (data not shown) or at 18 days after surgery
[F(7,24) = 0.479, P > 0.05] (Figure 3A). Motor function was
also not affected in all experimental groups at 18 days after
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FIGURE 2 | Reduction of dopamine and noradrenergic levels in a model of pre-motor PD. (A) Representative images of TH-staining in the substantia nigra pars
compacta (SNc) in the sham-operated animals (top panel), pre-motor model (middle panel), and model treated with EX-4 (bottom panel). Scale bars represent
500 µm. (B) Number of TH-positive cells in the SN expressed as cell density per mm3 (n = 6 animals per experimental group). A decrease in the number of
TH-positive cells was observed in the pre-motor model (unpaired t-test ∗∗P < 0.01). This decrease was partially prevented by treatment with EX-4 (unpaired t-test
Psham vs . model + EX−4 >0.05; Pmodel vs .model + EX−4 >0.05). (C) HPLC measurements of tissue levels of dopamine (DA) in SN, striatum and piriform cortex (PC)
expressed as ng/g wet weight. Levels of DA were reduced in the three regions (unpaired t-test n = 4–5 animals per group ∗∗P < 0.01, ∗∗∗∗P < 0.0001). (D) HPLC
measurements of tissue levels of noradrenaline (NA) in SN, striatum and piriform cortex (PC) expressed as ng/g wet weight. Levels of NA were reduced in the three
regions (unpaired t-test n = 4–5 animals per group ∗∗∗P < 0.001).
surgery (one-way ANOVA with repeated measures, P > 0.05)
(Figure 3B).
The Cognitive Deficit Displayed by the
Pre-motor PD Model Was Prevented by
Treatment With EX-4
Cognitive deficits were studied by comparing the discrimination
ratio (DR) score of all experimental groups over time (n = 4–5
Figure 3C). The DR score decreased over time across groups
[two-way ANOVA with repeated measures – F(2,39) = 23.784,
P < 0.05] and a statistically significant interaction effect between
the DR over time and experimental group was observed
[F(14,39) = 3.257, P < 0.001]. Cognitive deficits (indicated by
a decreased DR) were observed in the pre-motor model at
18 days after surgery (Figure 3C) and these deficits were already
present one week after surgery (data not shown). Treatment
with EX-4 prevented the cognitive deficit in the model and this
effect was mediated by GLP-1R activation as it was blocked by
co-administration of the competitive GLP-1R antagonist, EX9-39
(Figure 3C).
Hyposmia Displayed by the Pre-motor
PD Model Was Prevented by EX-4
Treatment
General olfactory function was investigated using the hidden food
test (Figure 4A). The pre-motor model displayed an increased
latency to finding the treat compared with the sham animals at
18 days after surgery (one-way ANOVA with Gabriel’s method
post hoc analysis, P < 0.05). Treatment with EX-4 prevented this
increase (Pmodel vs. model + EX−4 <0.05) by activation of GLP-1Rs,
as the latency displayed by animals treated with the double
toxins, EX-4 and pre-treatment with EX9-39, was similar to that
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FIGURE 3 | The pre-motor PD model displayed cognitive deficits that were prevented by treatment with EX-4, in the absence of anhedonia or motor dysfunction.
(A) At 18 days after surgery, the pre-motor model did not display anhedonia, as the percentage of sucrose consumed was similar in all experimental groups
(one-way ANOVA test n = 4–5 animals per experimental group – P > 0.05). Data are presented as mean % sucrose preference ± SEM. (B) Locomotion in the
pre-motor model receiving either saline (n = 5) or EX-4 (n = 4) treatments was tested at baseline and after treatment with either saline (model) or EX-4 (model + EX-4).
Data are presented as the mean latency (s) at which the animals fell from the rotating rod ± SEM. The latency after treatment in both groups (model and
model + EX-4 – Day 18) was similar to that observed at baseline (prior to DSP-4 injection) (one-way ANOVA with repeated measures; ns P > 0.05). (C) Cognitive
deficits, measured as a decrease in the discrimination ratio (DR) using a novel object recognition (NOR) test, were observed in the pre-motor model. EX-4 prevented
this deficit and the addition of the GLP-1R antagonist EX9-39 inhibited this effect (one-way ANOVA with Gabriel’s method post hoc analysis n = 4–5 animals per
experimental groups ∗P < 0.05, ∗∗∗P < 0.001).
displayed by the pre-motor model. Open food tests with the treat
in view were conducted to rule out a lack of motivation to find the
treat and latencies were similar in the three experimental groups
(t-test, P > 0.05 Figure 4B).
The habituation/dishabituation test was used to assess general
olfactory function (measure of the exploratory time for each
odor during each trial), odor memory (habituation) and odor
discrimination (dishabituation) at 7 days (Figure 4Ca) and
18 days after surgery (Figure 4Cb). General olfaction was affected
at 7 days after surgery in the model (Figure 4Ca). Exploration
times differed for the odors paprika, vanilla and social 2. Odor
memory was also impaired in the models as they did not
present a progressive decline in the exploration time over three
consecutive presentations of the social odors 7 days after surgery.
At 18 days after surgery, experimental groups differed in the
progressive decline of the exploration times for social 1 and
social 2 [Fsocial 1(18,32) = 3.115, P < 0.01; Fsocial 2(18,34) = 3.087,
P < 0.01]. Treatment with EX-4 increased the exploration time
on the first trial for social 1 (P< 0.05) and this effect was mediated
by GLP-1 receptor activation (P> 0.05) (Figure 4Cb). The ability
to discriminate between odors (dishabituation) was evaluated by
the increase in exploration time when a new odor was presented.
The pre-motor model displayed reduced exploration time for the
novel presentation of paprika and vanilla compared with sham
animals (Ppaprika <0.05; Pvanilla <0.05).
Neuroinflammation Is Present in the PC
of the Pre-motor PD Model
Specific markers for astrocytic response, GFAP, and microglial
activation, Iba1, were used to assess the presence of
neuroinflammation in the PC of the pre-motor PD model
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FIGURE 4 | The pre-motor PD model displayed hyposmia that was prevented
by treatment with EX-4. (A) Hyposmia was tested using the hidden food test
(sham n = 10; model n = 10; model + EX-4 n = 10; model + EX-4 + EX9-39
n = 5). Data are represented as mean ± SEM. The latency time (s) time taken
by the pre-motor model animals to find the hidden treat was increased
compared with that by the sham animals. Hyposmia was prevented by
treatment with EX-4 and this effect was inhibited when the animals received
the GLP-1R antagonist EX9-39 (one-way ANOVA with Gabriel’s method
post hoc analysis ∗P < 0.05). (B) Open food test. Animals were tested with
the treat in view and the latency time (s) in finding the treat was similar in all
experimental groups (unpaired t-test n = 5 animals per experimental group
P > 0.05). (C) Olfactory deficits were also tested using the
habituation/dishabituation test at baseline, a week after surgery (Ca) and
again at 18 days after surgery (Cb) (sham n = 10; model n = 10;
model + EX-4 n = 10; model + EX-4 + EX9-39 n = 5). (Ca) Two-way ANOVA
with repeated measures (trials 1, 2, and 3) revealed that the pre-motor group
differed in the progressive decline of the exploration time (s) for paprika
[Fpaprika(6,46) = 3.723, P < 0.05] 7 days after surgery. The pre-motor model
did not display the classical decline in exploratory time following the three
presentations of the social odors with an increase in the exploratory time at
trial 3 and no response following the presentation of the Social 1 odor and no
exploration of Social 2 odor. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001,
∗∗∗∗P < 0.0001 for pre-motor baseline compared with pre-motor at 7 days
after surgery. (Cb) At 18 days after surgery, the pre-motor model did not
explore the vanilla odor during the trials 2 and 3 or the two social odors
presented. EX-4 prevented the non-response following the first presentation
of the social 1 and 2 odors. This effect was inhibited by the addition of EX9-39
(two-way ANOVA with repeated measures – ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001 for
pre-motor model at baseline compared with pre-motor at 18 days after
surgery; & for pre-motor at 18 days after surgery compared with
pre-motor + EX-4; $ for pre-motor + EX-4 compared with
pre-motor + EX-4 + EX9-39; £ P < 0.05 for pre-motor model at baseline
compared with pre-motor + EX-4).
(Figure 5). At 18 days after surgery, a stronger GFAP staining
was observed in the PC of the model compared with that in
the sham animals (Figures 5Aa,b; P < 0.0001). GFAP-positive
astrocytes in all layers of the PC of the model displayed enlarged
somata, extensive branching processes and overlapping domains
(insert in Figure 5Aa). In contrast, a decrease in overall Iba1
staining intensity was observed in the PC of the pre-motor
model compared with that in the sham animals at 18 days after
surgery (Figures 5Ba,b; P < 0.05), reflecting a change in cell
morphology (Figure 5C). Iba1-positive microglia displayed a
decreased number of processes and less complex and shorter
branches in the PC of the pre-motor model than in the sham
animals, indicative of microglial activation (Figures 5Ca–f). The
size of the somata in the model was, however, similar to that
in the sham animals (P > 0.05; Figure 5Cg). Treatment with
EX-4 reduced the astrocytic activation in the PC of the model
(Figures 5Aa,b). However, EX-4 did not prevent microglial
activation in the model (Figures 5Ba,b).
Interestingly, neuroinflammation in the PC of the model was
already present a week after the stereotaxic injection and it
followed a rostro-caudal gradient at both 7 and 18 days after
surgery with a stronger staining observed in the anterior PC
than in the medial PC and lighter staining in the posterior PC
(Supplementary Figure S3). A stronger staining was observed at
18 days after surgery (Supplementary Figure S3).
Down Regulation of Interneuronal
Calcium Binding Proteins and Vasoactive
Intestinal Polypeptide (VIP) Is Observed
in the PC of the Pre-motor PD Model
To study the cellular structure of the PC in the pre-motor PD
model, the distributions of different classes of interneurons
were studied and compared with those in sham animals.
Interneurons were classified according to their calcium-binding
protein [parvalbumin (PV), calbindin (CB), calretinin (CR)]
or peptide content [cholecystokinin (CCK), somatostatin
(SOM), neuropeptide Y (NPY) and VIP]. Cell densities in
the PC of all experimental groups at 19 days after surgery
are presented in Table 2 and examples of the distributions
of PV-, CB- and CR-immunopositive interneurons of
the sham animals, pre-motor model and of the model
treated with EX-4 at 19 days after surgery are displayed in
Figures 6A–C. The number of PV, CB and CR- immunopositive
interneurons in the PC of the pre-motor model was significantly
reduced (Table 2 and Figures 6A–C Kruskal–Wallis test
P < 0.05); VIP-immunopositive interneurons were also
significantly reduced in number compared with the sham
animals (Kruskal–Wallis P < 0.05) (Table 2). In contrast,
the number of CCK-, SOM-, and NPY-immunopositive
interneurons in the PC of all experimental groups was similar
to that in the sham animals (Kruskal–Wallis test P > 0.05)
(Table 2).
The observed loss of the PV, CB, CR, and VIP-immunopositive
cells was prevented by treatment with EX-4 (Kruskal–Wallis
P < 0.05), but surprisingly, pre-treatment with the GLP-1R
antagonist EX9-39 only prevented the effect of EX-4 on
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FIGURE 5 | Neuroinflammation in the PC of the pre-motor PD model. (A) Astrocytic activation in the pre-motor PD model. (Aa) Representative immunohistochemical
staining of GFAP in a sham animal, model and model treated with EX-4. Scale bars for overview and for inserts represent 200 and 50 µm, respectively. (Ab)
Thresholding analysis of GFAP staining revealed an increase in the intensity in the pre-motor model compared with that in sham animals suggesting an activation of
astrocytes. This increase was prevented by treatment with EX-4 (unpaired t-test, ∗∗∗∗P < 0.0001). Data are represented as mean ± SEM. (B) Microglia activation in
the pre-motor PD model. (Ba) Representative immunohistochemical staining of Iba1 in a sham animal, model and model treated with EX-4. High magnification
image of one Iba1-positive cell for each condition is represented in the inserts. Scale bars for overview and for inserts represent 200 and 10 µm, respectively. (Bb)
Thresholding analysis of Iba1 staining revealed a decrease in the intensity in the pre-motor model compared with that in sham animals suggesting an activation of
microglia. This decrease was not prevented by treatment with EX-4 (unpaired t-test, ∗Pshamvs . model + EX−4 <0.05, Pmodelvs .model + EX−4 >0.05). Data are
represented as mean ± SEM. (C) Morphological characteristics of Iba1-immunopositive cells. (Ca) Neurolucida reconstructions of Iba1-positive cells in the sham,
model and model + EX-4. Each microglia branch is represented with a different color. Scale bars represent 20 µm. (Cb) Number of intersections between processes
of Iba1-positive cells and concentric sphere at different radius from the soma in the sham, model and model treated with EX-4 (Sholl analysis). Data are represented
as mean ± SD (n = 8 per experimental group – unpaired t-test – ∗∗P < 0.01 for pre-motor model compared with sham; && P < 0.01 for sham compared with
pre-motor model treated with EX-4). (Cc–g) The number of branches (Cc), total length (Cd), total surface (Ce), and the number of nodes (Cf) of Iba1-positive cells
were decreased in the pre-motor PD model compared with those in the sham animals. Treatment with EX-4 did not prevent this decrease. The size of cell somata
was similar in the sham, model and model + EX-4 (Cg). Data are represented as mean ± SD (n = 8 per experimental group – unpaired t-test ∗P < 0.05, ∗∗P < 0.01).
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TABLE 2 | Cellular densities of diverse interneuronal populations in the PC of the sham animals, sham animals treated with EX-4, pre-motor PD model and model treated
with EX-4.
SHAM + saline SHAM + EX-4 6-OHDA + DSP-
4 + saline
6-OHDA + DSP-
4 + EX-4
GAD-67 2587.8
(2247.6–2927.9)
2808.9
(2067.5–3550.3)
2610.7
(1908.9–3312.5)
2178.0
(1742.1–2613.9)
PV 1294.6
(576.5–2012.7)
950.23
(514.2–1386.2)
278.7 ∗∗∗∗
(136.6–420.8)
749.1 ####
(581.7–916.6)
CB 843.7
(591.3–1096.1)
1048.2
(668.2–1428.2)
110.6 ∗∗∗∗
(26.1–195.1)
834.2 ####
(403.6–1264.8)
CR 736.6
(487.1–986.0)
727.3
(309.0–1145.6)
171.8 ∗∗∗∗
(80.2–263.3)
772.2 ####
(473.8–1070.6)
CCK 172.2
(113.8–230.7)
195.7
(150.2–241.1)
139.7 (92.8–186.5) 164.8
(116.4–213.3)
SOM 619.7
(549.5–689.9)
414.4
(328.3–500.5)
439.8
(347.6–531.9)
436.0
(361.2–510.8)
NPY 173.7
(135.9–211.4)
202.2
(162.6.94–241.9)
167.6
(120.1–215.1)
145.8
(104.0–187.6)
VIP 472.8
(329.9–615.7)
424.9
(348.9–500.8)
224.5 ∗∗∗
(94.3–354.6)
482.6 ##
(295.5–669.6)
Data are represented as the median and interquartile range of the number cells per mm3 that are immunopositive for the indicated marker (n = 4–5 animals/per experimental
group). GAD-67, glutamic acid decarboxylase-67; PV, parvalbumin; CB, calbindin; CR, calretinin; CCK, cholecystokinin; SOM, somatostatin; NPY, neuropeptide Y; VIP,
vasoactive intestinal peptide (Kruskal–Wallis test was used, post hoc analysis for comparisons with Sham animals ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001;
post hoc analysis model compared with model treated with EX-4 #P < 0.05; ##P < 0.01; ###P < 0.001; ####P < 0.0001).
the CB staining. Although the addition of EX9-39 did not
completely prevent the protective effect of EX-4 (P > 0.05),
the intensity of the PV- and CR-staining was decreased
(Supplementary Figure S4). The study of the distributions
of the PV, CB, and CR interneurons in the toxin models
prior to EX-4 treatment (at 8 days after surgery) revealed
no significant changes in neurone numbers relative to sham
controls (Kruskal–Wallis test P > 0.05; Supplementary
Figure S5).
The number of GAD-67-immunopositive neurones was also
studied in the PC of all experimental groups to determine
whether the striking changes observed in the PC of the model
was due to a down-regulation of the calcium-binding proteins
and/or VIP or to loss of neurones. No significant difference was
found between the densities or distributions of GAD-67-positive
cells in the sham animals, in the pre-motor models and in
the models treated with EX-4, suggesting a down regulation
of the calcium-binding proteins PV, CB, CR, and peptide
VIP in the model rather than loss of cells (Table 2 and
Figures 7Aa,b).
Increased Number of
NeuN-Immunopositive Cells in the PC of
the Pre-motor PD Model
To further study the cellular structure of the PC in the pre-motor
PD model, the distribution of NeuN-immunopositive neurones
was observed in the PC of the sham animals and pre-motor model
at 18 days after surgery, revealing an increase in the number of
neurones in the model (Figures 7Ba,b – Psham vs. model <0.0001)
that resulted mainly from an increase in the number of neurones
in Layer 3 of the PC (data not shown). This increase was not
apparent at 8 days after surgery (Supplementary Figure S5) and
after treatment with EX-4 (Figures 7Ba,b – Pmodel vs. model + EX−4
<0.0001).
Degradation of the Perineuronal Nets
(PNNs) in the PC of the Pre-motor PD
Model
In view of the dramatic effects on PV interneurone staining
seen in the pre-motor model described above and the previously
described link between PNNs and PV neurones (Berretta et al.,
2015), the effects of the toxin injections on the integrity of
the PNNs in the PC in the pre-motor model were studied.
Sections were double labeled with the lectin Wisteria Floribunda
Agglutinin (WFA) and PV to determine whether the loss of
calcium-binding proteins was associated with a loss of PNNs.
Examples of the WFA+/PV+ staining of neurones in the
anterior PC of the sham animals, pre-motor PD model and
model treated with EX-4 are displayed in the top panels in
Figure 8A. The numbers of PV+/WFA+ neurones at day 8 and
19 after surgery are presented in Figures 8Ba,Ca. A significant
decrease in the number of PV+/WFA+ neurones was observed
in the PC of pre-motor model at 8 days after surgery when
compared with sham animals (P < 0.0001) (Figure 8Ba).
A further decrease was observed at 19 days after surgery
(P < 0.0001) (Figure 8Ca). Treatment with EX-4 prevented
the loss of both PV+ and WFA+ neurones in the pre-motor
model (P < 0.05) (Figure 8Ca). Pre-treatment with the GLP-1R
antagonist EX9-39 partially blocked the protective effects of
EX-4 treatment as assessed by PV+/WFA+ staining in the
pre-motor PD model (P< 0.01) (Figure 8Ca and Supplementary
Figure S4).
The PC also contained a small population of
PV-immunonegative (PV-) cells that were also surrounded
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FIGURE 6 | Distribution of calcium-binding proteins (CBPs) in the model of pre-motor PD. (A) Neuroprotective effect of EX-4 on parvalbumin (PV)-immunopositive
interneurons in the PC of the pre-motor model. (Aa) Example of PV-immunostaining in the anterior PC of sham animals, model and model + EX-4 treatment at
19 days after surgery. (Ab) Cell densities in the PC of all experimental groups at 19 days after surgery expressed as the number of PV-positive neurones per mm3.
The number of PV-positive interneurons was significantly decreased in the pre-motor model compared with that in the sham animals. Treatment with EX-4 prevented
this decrease. The distribution of PV-positive neurones following treatment with EX-4 and EX9-39 was similar to that in sham animals. (B) Neuroprotective effect of
EX-4 on calbindin (CB)-immunopositive interneurons in the PC of the pre-motor model. (Ba) Example of CB-immunostaining in the anterior PC of sham animals and
model with and without EX-4 treatment at 19 days after surgery. (Bb) Cell densities in the PC of all experimental groups at 19 days after surgery expressed as the
number of CB-positive neurones per mm3. A large decrease in the number of CB-positive interneurons was observed in the pre-motor model compared with the
sham animals. Treatment with EX-4 prevented this decrease following activation of GLP-1Rs as the distribution of CB-positive neurones was similar to that in the
pre-motor model. (C) Distribution of calretinin (CR)-immunopositive interneurons in the PC of the pre-motor model. (Ca) Example of CR-immunostaining in the
anterior PC of sham animals and model with and without EX-4 treatment at 19 days after surgery. (Cb) Cell densities in the PC of all experimental groups at 19 days
after surgery expressed as the number of CR-positive neurones per mm3. A decrease in the number of CR-positive interneurons was observed in pre-motor model
compared with the sham animals. Treatment with EX-4 prevented this decrease. The distribution of CR-positive neurones following treatment with EX-4 and EX9-39
was similar to that in the sham animals and pre-motor model treated with EX-4 only (Kruskal–Wallis test ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001).
by PNNs. A decrease in PV−/WFA+ cells in the PC of the
pre-motor model was observed at 8 days (Figure 8Bb) and
at 19 days after surgery (Figure 8Cb). Treatment with EX-4
prevented the loss of these PV−/WFA+ cells (P < 0.0001).
Finally, pre-treatment with EX9-39 partially blocked the
effects of EX-4 treatment in the pre-motor PD model
(P < 0.01) (Figure 8Cb and Supplementary Figure S4).
The WFA-immunopositive neurones were shown to be either
GABAergic (see GAD-67+/WFA+ staining in bottom panels
in Figures 8A,Cc) or GAD-67-immunonegative (Figure 8Cd).
Treatment with EX-4 prevented the loss of GAD-67+/WFA+
cells only (P < 0.001) (Figure 8Cc).
DISCUSSION
Detection of the loss of smell (hyposmia) in early-stage PD
patients (potentially as early as 10 years before diagnosis)
may greatly facilitate a clinical diagnosis and allow
neuroprotective-based treatments to commence that could
slow the progression of the disease and delay the onset of more
debilitating PD symptoms. However, the pathophysiological
changes behind hyposmia remain to be further characterized.
Despite a large number of studies on olfactory dysfunction in late
stage PD, none have specifically examined any possible structural
changes in the piriform cortex region. To address this, we used
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FIGURE 7 | Distribution of NeuN- and GAD-immunopositive neurones in the model of pre-motor PD. (A) Distribution of GAD-67-immunopositive interneurons in the
PC of the pre-motor model. (Aa) Example of GAD-67-immunostaining in the anterior PC of sham animals, model and model + EX-4 treatment at 19 days after
surgery. (Ab) Cell densities in the PC at 19 days after surgery expressed as the number of GAD-67-positive neurones per mm3. The distributions were similar in all
experimental groups. (B) Distribution of NeuN-immunopositive interneurons in the PC of the pre-motor model. (Ba) Example of NeuN-immunostaining in the anterior
PC of sham animals and models with and without EX-4 treatment at 19 days after surgery. (Bb) Cell densities in the PC at 19 days after surgery are expressed as the
number of NeuN-positive neurones per mm3 ± SEM. The density of NeuN-positive neurones in the pre-motor model increased compared with that in the sham
animals. This increase was prevented by treatment with EX-4. ∗∗∗∗P < 0.0001.
a dual neurotoxin-based model of pre-motor PD that displays
non-motor symptoms in the absence of motor symptoms, to
understand the etiology of hyposmia and specifically to detect
any changes in this region that may underlie this early symptom.
Neuroinflammation and PNN disruption were present in the
PC of the pre-motor PD model a week after toxin induction
and these changes were followed by a marked decrease of CBPs
and VIP in PC interneurons. Importantly, most of the observed
structural changes were prevented by EX-4 treatment, through
GLP-1R activation.
The Model of Pre-motor PD Displayed
Olfactory and Cognitive Deficits in the
Absence of Motor Dysfunction
Parkinson’s disease has been described as a multisystem disorder
that affects several body systems and neurotransmitters (Beach
et al., 2010; Klingelhoefer and Reichmann, 2017). The “dual-hit”
hypothesis described by Braak and colleagues (Braak et al.,
2003, 2004; Hawkes et al., 2007; Braak and Del Tredici, 2017)
proposed that a pathogen or virus is able to enter the brain
through two routes, the nose and the gut, leading to LP. The
pathology is then retrogradely spread through the brain via
synaptic connections reaching first the LC (stage 2), then the
SNc where it targets dopaminergic neurons resulting in the
hallmark motor symptoms of the pathology (stage 3), and later
the neocortex (stage 6). However, while the Braak staging theory
is accepted by most, the LP distribution in a large number of
patients, does not follow this ascending progression (Kalaitzakis
et al., 2008; Halliday et al., 2012) suggesting a selective neuronal
vulnerability based on their long-range connectivity, distinct
physiological properties and/or functional threshold (“threshold”
theory: Surmeier et al., 2017; Engelender and Isacson, 2017).
Accordingly, the early appearance of NMS in the prodromal
phase of the disease may be explained by a low “threshold” of
the peripheral, autonomic and enteric systems leading to a lack
of compensatory mechanisms to maintain their functions and
therefore an increased vulnerability of these regions (Engelender
and Isacson, 2017). The pathophysiological changes behind the
emergence of these NMS is, however, poorly understood and it is
still a matter of debate whether the depletion of neurotransmitters
rather than the early accumulation of α-synuclein in the olfactory
system is responsible for the olfactory dysfunction in PD
patients (Doty, 2017). While the induction of the pre-motor
model used in this study does not initiate the accumulation
of α-synuclein in brain regions affected in early stage PD, this
model was specifically used to study the effect of the partial
loss of NAergic and DAergic cells in the LC and SNc and
consequently of the reduction of the neurotransmitter levels in
these and connected regions. Importantly, the dual toxin-based
model of pre-motor PD enabled the investigation of the early
onset NMS in the absence of motor signs. Injections of both
DSP-4 and 6-OHDA resulted in a clear decrease in the number
of TH-immunopositive cells in the LC and SNc, respectively.
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FIGURE 8 | Effect of EX-4 on the distribution of perineuronal nets (PNNs) in the PC of the pre-motor model. (A) Slices of the anterior PC of sham animals, model
treated either with saline or EX-4 were double stained for PNNs (WFA in green) and PV (in red) (top row) and for PNNs (WFA in red) and GAD-67 (in green) (bottom
row) at 19 days after surgery. (B) Cell densities in the PC of the sham animals and toxin-treated animals at 8 days after surgery expressed as the number of
WFA-positive and PV-positive neurones per mm3 (Ba) and as the number of WFA-positive and PV-negative neurones per mm3 (Bb). A decrease in the number of
both WFA+/PV+ and WFA+/PV– cells was observed compared with that in the sham animals and models. (Ca) Densities of WFA+/PV+ neurones in the PC of the
pre-motor model were decreased compared with that in sham animals at 19 days after surgery. The decrease was prevented by treatment with EX-4 and the
addition of EX9-39 inhibited the effect of EX-4 in the model. (Cb) Densities of WFA+/PV– neurones in the PC of the model were also decreased compared with that
in sham animals at 19 days after surgery. EX-4 prevented the decrease in the number of WFA+/PV– cells. Densities of WFA+/GAD+ neurones (Cc) and WFA+/GAD–
neurones (Cd) in the PC at 19 days after surgery were decreased in the model compared with that in the sham animals. Treatment with EX-4 prevented the
decrease of WFA+/GAD+ neurones only (Kruskal–Wallis test ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001).
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Dopaminergic and noradrenergic lesions resulted in a decrease
of∼50% of DA and NA levels in the SNc of the pre-motor model
and behavioral assessments revealed that significant olfactory
and cognitive deficits were displayed by the model without
anhedonia or motor dysfunction. This suggests that this model
may represent an earlier stage of the disease than in previously
described animal models in which anxiety and depression-like
symptoms, cognitive deficits or olfactory dysfunctions were
reported in the presence (albeit limited) of motor dysfunctions
(Tadaiesky et al., 2008; Santiago et al., 2010; Carvalho et al., 2013;
Costa et al., 2014; Faggiani et al., 2015; Ledreux et al., 2016;
Nezhadi et al., 2016). The development of animal PD models
focusing mainly on the nigrostriatal DAergic system has provided
valuable insight into the etiology of motor symptoms of PD for
many decades; however, each model has its own strengths and
limitations and none of them recapitulates all the symptoms
of the disease exactly (Grandi et al., 2018; Vingill et al., 2018).
While a loss of DA results in a loss of motor function in these
models, non-motor symptoms of PD cannot be accounted for
by the DA depletion alone, suggesting an implication of other
neurotransmitters, including NA, in the etiology of these deficits
(Delaville et al., 2011). Although impairments of both DAergic
and NAergic systems have been shown in the human disease
(Jenner et al., 1983; Gaspar et al., 1991; Buddhala et al., 2015;
Nahimi et al., 2018; Peterson and Li, 2018), the implication of
NA in the disease progression has often been ignored, hence the
focus on DA depletion alone in animal models (with addition of
uptake inhibitors to prevent the effect of 6-OHDA on NAergic
cells in most studies). The pre-motor model used in this study
displayed a moderate NA depletion combined with a moderate
DA loss that resulted in non-motor symptoms (hyposmia and
cognitive deficits) in the absence of motor deficit 24/25 days after
the injection of DSP-4. The combination of the depletions was
essential for the appearance of olfactory deficits in the pre-motor
PD model, as depletion of either DA alone or NA alone (using
the same low toxin concentrations) was not sufficient to elicit
hyposmia in both hidden and habituation/dishabituation tests
in the treated animals (data not shown). This is in agreement
with previous studies that show PD patients with dopamine
beta-hydroxylase (DBH) deficiency displaying a normal olfactory
function (Garland et al., 2011) and an intact odor detection
performance following NA depletion in the OB (Doty et al.,
1988).
Hyposmia, characterized by the inability to perceive,
recognize, and discriminate or memorize odors, occurs in ∼90%
of PD patients (Doty et al., 1988; Mesholam et al., 1998; Berendse
et al., 2011; Doty, 2012). It is thought to be an early event
occurring several years prior to clinical diagnosis and to be a
good predictor of cognitive decline in neurodegenerative diseases
and therefore a reliable aid to early PD diagnosis (Devanand
et al., 2010; Berendse et al., 2011; Doty, 2012, 2017). Impaired
olfactory function and a reduced ability to learn odors (shown
by impaired habituation), indicative of cognitive deficits, were
observed in our model as early as 7 days after toxin-injection.
These olfactory deficits were unlikely to have resulted from
reduced motivation, since the number of TH-immuno-positive
cells in the VTA (a dopaminergic brain area known to be
involved in cognition, motivation and emotion) was not affected
by the 6-OHDA toxin injection and the animals were able to
locate visible treats during an open food test. Like PD patients
(Doty, 2012), the rats were hyposmic, but not anosmic, as
animals found the treat in the hidden food test and displayed
exploratory activity in the habituation/dishabituation test. We
cannot preclude a role of the cognitive deficit on olfaction as
odor detection, identification, discrimination or memory rely
upon each other for a normal olfactory function. However, the
striking PC structural changes, observed in this study, may also
be responsible for the compromised olfactory function observed
in the pre-motor model.
Role of Noradrenergic and Dopaminergic
Inputs Into the Piriform Cortex in the
Early Stage of PD
Poor olfactory performance in PD patients has been associated
with a volume reduction in the olfactory bulbs (Brodoehl et al.,
2012; Altinayar et al., 2014; Li et al., 2016) and PC (Wattendorf
et al., 2009; Chen et al., 2014; Lee et al., 2014) and the severity of
the disease correlates directly with the severity of the deficit in the
PC (Wattendorf et al., 2009). A profound hyperactivation in the
PC of hyposmic PD patients, subjected to an odor detection task
and the consequent network dysfunction (Moessnang et al., 2010)
may be attributed to the loss of dopaminergic and noradrenergic
inputs to the PC, as shown in this model (with a 40% loss of both
neurotransmitters) and in a previous study (Becker et al., 2018),
that would normally have local “dampening” effects by increasing
interneuronal spontaneous activity (Gellman and Aghajanian,
1993; Hasselmo et al., 1997; Giorgi et al., 2003, 2006).
The existence of long-range noradrenergic innervation in the
piriform cortex and its influence on synaptic plasticity/neuronal
function is indeed now well established (Fallon and Moore,
1978; Constanti and Sim, 1987; Bouret and Sara, 2002; Ghosh
et al., 2015; Vadodaria et al., 2017). Likewise, dopaminergic
projections into the PC may be important in olfactory-guided
learning (Garske et al., 2013) as well as the maintenance of
PV-expressing interneurons and pyramidal neurone morphology
(Stanwood et al., 2001). In addition to these important synaptic
functions, there is now considerable evidence favoring a general
intrinsic neuroprotective role for these neurotransmitters in
the brain (noradrenaline: O’Neill and Harkin, 2018; dopamine
and dopamine receptor agonists: Schapira, 2002; Olguín et al.,
2018; Tozzi et al., 2018). Dopamine agonists also possess
anti-α-synuclein protein aggregation properties (Luo et al.,
2016; Yedlapudi et al., 2016). The neuroprotective effects of
dopamine agonists accord well with their now well-established
use in the treatment of early Parkinson’s disease (Marsili
et al., 2017) and could involve a variety of underlying
mechanisms including antioxidation, ROS scavenging and
inhibition of apoptosis (Bonuccelli and Pavese, 2007). Thus, it
is reasonable to propose that the neuroinflammation, structural
and interneuronal calcium binding protein changes we observed
in the PC following dual toxin treatment, were the direct
result of a reduction in background neuroprotection normally
offered by noradrenergic and dopaminergic inputs into this area.
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The consequent interference with local circuit function could
then be responsible for the behavioral changes in olfaction
that were characteristic of our model, which were effectively
prevented by EX-4 treatment.
Neuroinflammation Is Present in the PC
of the Pre-motor PD Model
Hyposmia observed in the model of pre-motor PD was associated
with striking changes in the PC, including neuroinflammation
and cellular changes. Activated astrocytes were observed in the
PC of the model of pre-motor PD at 19 days after surgery.
Observation of the GFAP staining also revealed that an increased
level of neuroinflammation in the PC of the pre-motor model
compared with that in sham animals was already present at
8 days after surgery with a stronger staining in the anterior
PC. Activation of astrocytes was progressive in nature and
followed a rostro-caudal gradient suggesting that glial cells in
the anterior PC may therefore activate neighboring cells via gap
junctions, with the release of toxic pro-inflammatory factors
as previously suggested (Lucin and Wyss-Coray, 2009) leading
to the progression of neuroinflammation across the PC region.
An apparent decline in Iba1 overall intensity in the PC of the
pre-motor model was also observed. This decline was due to
changes in cell morphology, including a decreased number of
protruding branches and shorter processes, typical of microglial
activation (Block and Hong, 2005; Wang et al., 2015).
Neuroinflammation has been shown to be involved in PD
pathogenesis with the synergic activation of both astrocytes
and microglia contributing to an enhanced death of DAergic
neurones in the SNc (Glass et al., 2010; Iannaccone et al., 2013;
Wang et al., 2015). The cause of neuroinflammation and the
specific roles of astrocytes and microglia in the development
of the disease remain poorly understood. However, both DA-
mediated toxicity and the release of pro-inflammatory cytokines
released by activated microglia and astrocytes are thought to
play a vital role in the degeneration of DA neurones (Rabinovic
et al., 2000; Ferrari et al., 2006; Caudle et al., 2007; Lecours
et al., 2018). As the disease progresses, these degenerative
neurones then amplify the inflammatory responses and the
process of neurodegeneration by releasing molecules such as
α-synuclein and adenosine triphosphate (ATP) that further
enhance microglia activation (Davalos et al., 2005). The presence
of neuroinflammation in the PC of the pre-motor model may
also potentially be attributed to the decrease in NAergic inputs
to this region as NA has the ability to suppress microglial pro-
inflammatory activity through activation of microglial adrenergic
receptors; furthermore, reduced levels of NA have been associated
with progressive neuronal degeneration in both AD and PD
patients (Heneka et al., 2010; Kong et al., 2010; Vermeiren and
De Deyn, 2017; O’Neill and Harkin, 2018).
Are Cellular Changes Observed in the
PC, Potential Landmarks for
Pre-motor PD?
This study examined the pathophysiological changes occurring
in the olfactory cortex of a PD model for the first time. Striking
cellular changes were observed following both noradrenergic
and dopaminergic lesions. Interestingly, the number of
NeuN-immunopositive neurones increased in the PC of the
pre-motor PD model compared with that in the sham animals.
Although the cause of this increase remains unknown, it is
possible that structural changes observed in the PC of the model
caused by degradation of the PNNs resulted in a reorganization
of neurones in this brain area. PNNs are highly condensed ECM
aggregates that form honeycomb structures around PV-positive
interneurons in several brain regions including the PC (Alpár
et al., 2006; Ajmo et al., 2008) and around glutamatergic neurones
in the parietal cortex, the hippocampal CA2 region, the amygdala
and PC (Härtig et al., 1999; Brückner et al., 2004; Carstens
et al., 2016; Morikawa et al., 2017). We can hypothesize that the
disruption of the PNN and therefore the extracellular matrix
may result in the migration of the cells away from their original
laminar location. Although a disruption of lamination has yet to
be described in PD patients to date, such a disruption has been
associated with epilepsy (Chae et al., 1997). Reeler is a transgenic
mouse model caused by the autosomal recessive genetic mutation
in reelin – a secretory ECM protein (D’Arcangelo et al., 1997).
The disruptive lamination in this mouse model is the result of
defective formation of the CNS, whilst the CNS in the pre-motor
PD model was intact prior to toxin administration. However,
the possible link between a disrupted lamination, deficits in
the ECM and occurrence of epilepsy found in previous studies
(Saghatelyan et al., 2001; Dityatev et al., 2007, 2010) may suggest
that the loss of distinct PC layers in the pre-motor PD model is
the result of an ECM disruption.
This PNN degradation was observed at 8 days after surgery
and coincided with the presence of activated astrocytes in this
region. Although the cause of the PNN degradation is unknown,
one could speculate a role of inflammation in this process (Baig
et al., 2005; Hobohm et al., 2005). The loss of PNNs may reflect a
defect in the ability of glial cells to secrete vital PNN components,
e.g., chondroitin sulfate proteoglycans (CSPGs) (Faissner et al.,
2010; Klausmeyer et al., 2011; Wiese et al., 2012). However,
whether the secretion and production of extracellular matrix
proteins by activated glia is altered under chronic inflammatory
conditions in the pre-motor model has yet to be determined.
Alternatively, degradation of PNNs in the PC may result from
the secretion of matrix metalloproteinase-9 (MMP-9) and a
disintegrin-like and metalloproteinase with thrombospondin
motifs (ADAMTS) from reactive astrocytes and neurones as
shown in an epilepsy model (Pollock et al., 2014; Dzyubenko
et al., 2016). Inflammatory microglial activation may also lead to
degradation of the PNNs (Franklin et al., 2008).
Although the role of PNNs surrounding PC pyramidal cells
is undetermined, PNNs have been shown to restrict synaptic
plasticity in the hippocampal CA2 pyramidal cells (Carstens
et al., 2016). Loss of PNNs may also render interneurons
more susceptible to oxidative stress due to astrocytic activation
as early as 8 days after surgery, potentially leading to a
reduction of PV mRNA expression and a potential disruption
of oscillatory activity as previously shown in the hippocampus
(Yamada et al., 2015; Sun et al., 2018). The number of
GAD-immunopositive neurones in the PC of the pre-motor
Frontiers in Cellular Neuroscience | www.frontiersin.org 15 December 2018 | Volume 12 | Article 479
fncel-12-00479 December 10, 2018 Time: 12:0 # 16
Sancandi et al. PC Changes in PD Model
model was similar to that in the sham animals, suggesting
a downregulation of CBPs rather than neuronal death. The
dramatic decrease in the CBP expression in the PC (mimicking
the vulnerability of these cells in olfactory regions of PD
patients; Ubeda-Banon et al., 2010; Doty, 2012), will eventually
lead to a disruption of calcium buffering and cell death due
to calcium toxicity. The downregulation of CBPs is likely to
modulate the firing of interneurons in the PC of the pre-motor
model and their targets (Caillard et al., 2000; Volman et al.,
2011), potentially disturbing the excitation/inhibition balance
in this region and ultimately altering behavioral performance
on smell identification/discrimination as previously shown in
Alzheimer’s disease and PD patients (Li et al., 2010; Moessnang
et al., 2010). The characterization of potential compensatory
mechanisms in other brain regions as a consequence of these
changes, was beyond the scope of this study and remains to be
explored.
Further studies are also needed to determine the timing
of the observed changes. Although the number of PV- and
CB-immunopositive cells and VIP-positive cells was similar to
that in the sham animals at 8 days after surgery, changes may
have occurred earlier, but not have been visible until the system
had failed to replace the existing CBPs. Similar considerations
may explain the differential effect of the antagonist EX9-39 on
the number of PV- and CR-positive neurones compared with that
on CB-positive interneurons. Although the number of PV- and
CR-neurones after treatment with EX9-39 was similar to that
with EX-4, the intensity of the staining was lower, possibly
suggesting a slower downregulation of these calcium binding
proteins that did not result in a visible decrease in the number
of neurones in the time course of the protocol used in this
study.
EX-4, a Promising New Treatment for
Pre-motor PD?
The pre-motor model of PD provided further understanding of
the early pathology of PD and a means to test a potential new
therapy, EX-4. The presence of GLP-1 – producing cells in the OB
and the known presence of EX-4 target, GLP-1Rs, in the PC (Cork
et al., 2015; Thiebaud et al., 2016) led us to investigate the effect
of EX-4 on the striking cellular changes observed in this region
following dual neurotoxin treatment. Injections of EX-4 in sham
animals had no effect on the animal behaviors (Supplementary
Figure S6), level of inflammation or PC neuronal distributions
(Table 2). However, EX-4 administration in the pre-motor model
of PD prevented astrocytic activation, olfactory and cognitive
impairments, the loss of PNNs and the reduction of some CBPs
and VIP expression in the PC, through GLP-1R activation, since
the effects were prevented by the competitive GLP-1R antagonist
EX9-39.
EX-4 has been found to exert powerful neuroprotective
properties in several other experimental neurodegenerative
disease model systems including PD and Alzheimer’s disease
(for review see Athauda and Foltynie, 2016a,b; Athauda and
Foltynie, 2018), Huntington’s disease (Martin et al., 2009),
amyotrophic lateral sclerosis and stroke (Hölscher, 2014)
and other neuroinflammatory diseases (multiple sclerosis:
Lee et al., 2018). However, the mechanism(s) by which EX-4
and other GLP1-R agonists exert these effects is still unclear.
It has been suggested that such neuroprotective effects as
well as general cell-protective effects on other cell systems
(pancreatic β-cells: Li et al., 2013; adipocytes: Wang et al., 2017;
Góralska et al., 2017; cardiomyocytes: Chang et al., 2018; hepatic
cells) could be exerted via an improvement of mitochondrial
function compromised by oxidative stress [reactive oxygen
species (ROS) production]. The molecular defense mechanisms
involved are likely to be varied and complex in different cells,
however, sustaining mitochondrial membrane potential to
prevent mitochondrial apoptosis and ultimate cell death could
be a common factor governing effectiveness (Cunha et al.,
2009). Of particular interest and relevance to the present study
was a report by Song et al. (2018) showing that depletion
of brain noradrenaline by DSP-4 treatment in mice, was
linked to neuroinflammation, ROS production and subsequent
neurodegeneration; moreover, it was proposed that nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase-2 (NOX2)
was involved in the inflammation-mediated production of
superoxide. The link between chronic neuroinflammation,
microglial activation, oxidative stress (ROS production),
mitochondrial dysfunction and PD pathophysiology was recently
reviewed by Hassanzadeh and Rahimmi (2018), in which it is
suggested as a general strategy, that alternative antioxidative
and anti-inflammatory treatments for PD could replace or
supplement existing therapies in the near future. We would
advocate that use of EX-4 or other GLP-1R agonists could be
part of this alternative treatment strategy, with the potential to
improve the long-term prognosis for millions of PD patients
world-wide.
To summarize, the model of pre-motor PD we have
investigated, exhibited clear hyposmia, a recognized early
characteristic of clinical PD. Olfactory deficits were associated
with the presence of neuroinflammation in the PC, potentially
leading to a disruption of PNNs and eventually a downregulation
of CBPs and VIP from distinct local interneurons. The fact that
these effects were prevented by EX-4 treatment indicates that this
model may provide a means for research into early PD treatment.
The future investigation of a GLP-1 therapeutic target system may
lead to the possibility of earlier intervention for PD patients and
a delay of disease progression.
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FIGURE S1 | (A) Representative images of TH-staining in the locus coeruleus (LC)
in the sham-operated animals (left panel), pre-motor PD model (middle panel), and
model treated with EX-4 (right panel). Scale bars represent 200 µm. (B) Number
of TH-positive cells in the LC expressed as a percentage of sham (n = 4 animals
per experimental group). The DPS-4 injections resulted in a decrease in the
number of TH-positive cells in the LC of pre-motor model or model treated with
EX-4 (unpaired t-test P < 0.05). This decrease was prevented by treatment with
EX-4 (unpaired t-test P < 0.05). ∗P < 0.05; ∗∗∗P < 0.001.
FIGURE S2 | (A) Representative images of TH-staining in the ventral tegmental
area (VTA) in the sham-operated animals (left panel), pre-motor PD model (middle
panel), and model treated with EX-4 (right panel). Scale bars represent 500 µm
substantia nigra pars compacta (SNc). (B) Number of TH-positive cells in the VTA
expressed as cell density per mm3 (n = 6 animals per experimental group). The
double toxin injections had no effect on the number of TH-positive cells in the VTA
of pre-motor model or model treated with EX-4 (unpaired t-test P > 0.05).
FIGURE S3 | GFAP-positive activated astrocytes follow a rostro-caudal gradient in
the piriform cortex (PC) of the pre-motor PD model at both 8 days (A–C) and
19 days (D–F) after surgery with a stronger staining in the anterior PC (A,D) than
in the medial (B,E), and posterior (C,F) regions. At 8 days after surgery, activated
GFAP+ astrocytes, characterized by overlapping astrocytic domains (insert in A)
were only found in the anterior PC (A) and the GFAP-immunopositive cortical
surface was more intensely stained in the anterior PC than in the medial (B) and
posterior PC (C). GFAP staining at 19 days after surgery was stronger in all PC
regions compared with that at 8 days after surgery and overlapping astrocytic
domains were observed in the anterior (insert in D) and medial (insert in E) PC of
the pre-motor model.
FIGURE S4 | Example of PV-, CB-, CR-, and PNN+/PV+-immunostaining in the
anterior PC of the model of pre-motor PD treated with EX-4 and GLP-1 antagonist
EX9-39 at 19 days after surgery. Pre-treatment with the GLP-1R antagonist
EX9-39 only prevented the effect of EX-4 on the CB staining. Although the
addition of EX9-39 did not completely prevent the protective effect of EX-4
(P > 0.05), the intensity of the PV- and CR-staining was decreased. Pre-treatment
with the GLP-1R antagonist EX9-39 partially blocked the protective effects of EX-4
treatment as assessed by PV+/WFA+ staining in the pre-motor PD model.
FIGURE S5 | (A) Density of NeuN-positive neurones in the sham and pre-motor
PD model at 8 days after surgery. (B) Density of CR-immunopositive neurones in
the sham and toxin-treated animals at 8 days after surgery. (C) Density of
PV-immunopositive neurones in the sham and toxin-treated animals at 8 days
after surgery. (D) Density of CB-immunopositive neurones in the sham and
toxin-treated animals at 8 days after surgery. The number of PV-positive neurones
remained unchanged in all experimental groups. Cell densities are expressed as
the number of immune-positive neurones per mm3 ± SEM (Kruskal–Wallis test
was used the number of neurones remained unchanged between the two groups).
FIGURE S6 | Effect of EX-4 injections on sham animals. (A) Cognitive function
was tested in the sham animals treated with EX-4 only (n = 4). There was no
change in the DR in these animals compared with sham animals (unpaired t-test
P > 0.05). (B) Sham rats treated with EX-4 did not display anhedonia (n = 4
unpaired t-test P > 0.05). (C,D) Hyposmia in the sham animals treated with EX-4
was tested using the hidden food (C) and habituation and dishabituation (D) tests
(n = 10). The latency time (s) taken by the sham animals treated with EX-4 to find
the hidden treat was similar to that taken by the sham animals (unpaired t-test
P > 0.05). Exploration times (s) following the three presentations of all odors were
similar in the sham and sham treated with EX-4 (unpaired t-test P > 0.05).
(E) Representative immunohistochemical staining of GFAP in a sham animal
treated with EX-4. Inserts represent high magnification of one astrocyte. Scale bar
for overview represents 200 µm.
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